Sight Sciences (SGHT) said late Tuesday that a 36-month study evaluating the long-term effectiveness of its OMNI Surgical System in treating primary open-angle glaucoma demonstrated sustained reductions in intraocular pressure and medication use.
Mean intraocular pressure reductions ranged from 5.6 mmHg to 7.1 mmHg with greater declines in patients with higher baseline, the company said.
The results show significant decreases in utilization of medications through 18 months postoperatively, the company added.
The study evaluated 230 eyes of 196 patients with primary open-angle glaucoma.
Shares of the company were up 1.5% in recent after-hours activity.
Price: 3.36, Change: +0.05, Percent Change: +1.51
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。